Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $500K | $500K | $500K | $500K | $500K | $500K | — | — | — |
| Revenue growth | — | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Operating income | -$20.6M | -$18.5M | -$21.1M | -$20.6M | -$18.5M | -$21.0M | -$24.9M | -$21.0M | -$19.1M | -$14.7M |
| Operating margin | — | -3693.7% | -4213.0% | -4113.1% | -3697.3% | -4201.4% | -4984.3% | — | — | — |
| Net income | -$22.1M | -$20.4M | -$11.9M | -$16.9M | -$21.5M | -$20.8M | -$35.9M | -$19.5M | -$18.6M | -$14.5M |
| Net margin | — | -4080.4% | -2376.7% | -3370.3% | -4296.7% | -4153.9% | -7179.6% | — | — | — |
| EPS (diluted) | -$11.89 | -$2.72 | -$0.68 | -$0.77 | -$10.08 | -$3.83 | -$5.03 | -$2.16 | -$16.94 | -$6.83 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$18.4M | -$16.6M | -$7.04M | -$20.3M | -$15.6M | -$16.2M | -$23.1M | -$19.0M | -$18.9M | -$13.9M |
| Capital expenditures | $62.5K | $38.6K | $138K | $349K | $19.1K | $312K | $268K | $452K | $29.5K | $281K |
| Free cash flow | -$18.4M | -$16.7M | -$7.18M | -$20.6M | -$15.6M | -$16.5M | -$23.4M | -$19.5M | -$18.9M | -$14.2M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $2.62M | $11.4M | $13.4M | $6.88M | $17.2M | $19.6M | $11.5M | $5.84M | $5.87M | $8.78M |
| Total assets | $30.8M | $47.5M | $46.9M | $38.3M | $37.5M | $74.0M | $44.0M | $21.9M | $9.72M | $12.3M |
| Total liabilities | $24.1M | $20.8M | $26.0M | $23.7M | $18.9M | $18.3M | $14.6M | $8.53M | $5.47M | $5.23M |
| Long-term debt | — | — | $9.42M | $9.80M | $5.05M | $5.85M | $5.96M | — | — | — |
| Shareholders' equity | $6.73M | $26.7M | $20.9M | $14.6M | $18.6M | $55.8M | $29.3M | $13.4M | $4.24M | $7.06M |
| Retained earnings | -$241M | -$262M | -$274M | -$291M | -$312M | -$333M | -$369M | -$388M | -$407M | -$421M |
| Shares (wtd avg diluted) | 2.23M | 17.3M | 18.8M | 23.3M | 2.71M | 5.43M | 7.14M | 9.05M | 1.10M | 2.12M |
Every figure is extracted from Imunon, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.